Vertex Pharmaceuticals has announced new data on CASGEVY, including clinical findings in children aged 5-11 years with sickle cell disease or transfusion-dependent beta thalassemia. The therapy shows transformative potential in younger patients, with efficacy and safety data consistent with its benefits in older patients. Vertex plans to submit global regulatory applications for CASGEVY in children aged 5-11 in the first half of 2026. The data, presented at the American Society of Hematology Annual Meeting, includes the first clinical data for children aged 5-11 and longer-term data for patients aged 12 and older. The therapy has been approved for patients aged 12 and older in the US, UK, EU, Saudi Arabia, Bahrain, Kuwait, Qatar, Canada, Switzerland, and the UAE. Vertex's Carmen Bozic highlights the therapy's transformative potential, while Haydar Frangoul, a medical director, expresses excitement about offering the therapy to younger patients. The data reveals successful outcomes in children aged 5-11, with no vaso-occlusive crises and transfusion independence. Longer-term data for patients aged 12 and older further confirms the therapy's benefits. The safety profile remains consistent with myeloablative conditioning and autologous transplant. Sickle cell disease and transfusion-dependent beta thalassemia are discussed, with details on their impact on patients' health and quality of life. CASGEVY, a gene-edited cell therapy, is designed to increase fetal hemoglobin production, reducing vaso-occlusive crises and transfusion needs. The CLIMB studies, including CLIMB-111, CLIMB-121, CLIMB-141, and CLIMB-151, assess CASGEVY's safety and efficacy. Vertex emphasizes the importance of further studies and the potential of CASGEVY in transforming patient care.
